Nodal aggressive B-cell lymphomas: A diagnostic approach

Journal of Clinical Pathology

Volumn 60, Issue 10, 2007, Pages 1076-1085

  Prakash, Sonam ^a   Swerdlow, Steven H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL LEUKEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPHOBLASTOMA; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 35349012681     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.039263     Document Type: Review

References (108)

1. Rappaport H. Tumors of the hematopoietic system. Washington, DC: Armed Forces Institute of Pathology, 1966.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
3. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974;34(4 Suppl):1488-503.
4. Gerard-Marchant R, Hamlin I, Lennert K, et al. Classification of non-Hodgkin's lymphomas. Lancet 1974;2:406-8.
5. Lennert K, Collins RD, Lukes RJ. Concordance of the Kiel and Lukes-Collins classifications of non-Hodgkin's lymphomas. Histopathology 1983;7:549-59.
6. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas [correction appears in Lancet 1988;1:372]. Lancet 1988;1:292-3.
7. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
8. Tbakhi A, Edinger M, Myles J, et al. Flow cytometric immunophenotyping of non-Hodgkin's lymphomas and related disorders. Cytometry 1996;25:113-24.
9. Cook JR, Shekhter-Levin S, Swerdlow SH. Utility of routine classical cytogenetic studies in the evaluation of suspected lymphomas: results of 279 consecutive lymph node/extranodal tissue biopsies. Am J Clin Pathol 2004;121:826-35.
10. Brunning RD, Borowitz M, Matutes E, et al. Precursor B lymphoblastic leukaemia/lymphoblastic lymphoma (precursor B-cell acute lymphoblastic leukaemia). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:111-14.
11. Dong HY, Liu W, Cohen P, et al. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in Merkel cell carcinoma and small cell carcinomas. Am J Surg Pathol 2005;29:687-92.
12. Swerdlow SH, Berger F, Issacson PG, et al. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours.Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2001:168-70.
13. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-27.
14. Nodit L, Bahler DW, Jacobs SA, et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Human Pathol 2003;34:1030-4.
15. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101:4975-981.
16. Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997;89:1421-9.
17. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315-21.
18. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97.
19. Camacho FI, Garcia JF, Cigudosa JC, et al. Aberrant Bcl6 protein expression in mantle cell lymphoma. Am J Surg Pathol 2004;28:1051-6.
20. Swerdlow SH, Williams ME. From centrocyte to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol 2002;33:7-20.
21. Gaffer KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours.Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:171-4.
22. Loeffler M, Shipp M, Stein H. Report on the workshop: "Clinical consequences of pathology and prognostic factors in aggressive NHL". Ann Hematol 2001;80(Suppl 3):B8-12.
23. Lim MS, Beaty M, Sorbara L, et al. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol 2002;26:1458-66.
24. Fraga M, Sanchez-Verde L, Forteza J, et al. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology 2002;41:216-29.
25. Natkunam Y, Warnke RA, Zehnder JL, et al. Blastic/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases. Am J Surg Pathol 2000;24:525-34.
26. Chu PG, Loera S, Huang Q, et al. Lineage determination of CD20- B-cell neoplasms: an immunohistochemical study. Am J Clin Pathol 2006;126:534-44.
27. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996;94:318-23.
28. Kambham N, Kong C, Longacre TA, et al. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 2005;13:304-10.
29. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846-52.
30. King BE, Chen C, Locker J, et al. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. Mod Pathol 2000;13:1219-31.
31. Natkunam Y, Warnke R, Alizadeh A, et al. BCL-6 protein expression predicts improved survival in patients with diffuse large B-cell lymphoma. Mod Pathol 2001;14:1017.
32. Skinnider BF, Horsman DE, Dupuis B, et al. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999;30:803-8.
33. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-21.
34. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
35. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
36. Zinzani PL, Dimhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue microarrays. Haematologica 2005;90:341-7.
37. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
38. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-43.
39. Rantanen S, Monni O, Joensuu H, et al. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 2001;42:1089-98.
40. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse Targe B-cell lymphoma. Blood 1998;92:3152-62.
41. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996;87:265-72.
42. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-51.
43. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996;88:1046-51.
44. Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998;16:1931-9.
45. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961-8.
46. Mounier N, Briere J, Gisselbrecht C, et al. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 2006;91:715-6.
47. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-13. Erratum: Blood 2007;109:2292.
48. Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994;83:1757-9.
49. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;99:2285-90.
50. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999;17:1558-67.
51. Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol 1998;9:55-61.
52. Au WY, Horsman DE, Gascoyne RD, et al. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leukemia Lymphoma 2004;45:519-28.
53. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28:736-47.
54. Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV positive and negative patients. Ann Oncol 2004;15:1673-9.
55. Teruya-Feldstein J. Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep 2005;7:357-63.
56. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-20.
57. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12.
58. Young KH, Chan WC, Fu K, et al. Mantle cell lymphoma with plasma cell differentiation. Am J Surg Pathol 2006;30:954-61.
59. Simonitsch-Klupp I, Hauser I, Ott G, et al. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia 2004;18:146-55.
60. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997;89:1483-90.
61. Reichard KK, McKenna RW, Kraft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol 2007;20:310-19.
62. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of six cases. Blood 2003;102:2568-73.
63. De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CTLC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003;102:2638-41.
64. Onciu M, Behm FG, Downing JR, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of two cases. Blood 2003;102:2642-4.
65. Barth TF, Leithauser F, Joos S, et al. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 2002;3:229-34.
66. Banks PM, Warnke RA. Mediastinal (thymic) large B-celi lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:175-6.
67. Paulli M, Strater J, Gianelli U, et al. Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 1999;30:178-87.
68. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB. 1, and PU. 1 in the absence of immunoglobulins. Am J Pathol 2003;162:243-53.
69. Calaminici M, Piper K, Lee AM, et al. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 2004;45:619-24.
70. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002;15:1172-80.
71. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001;30:393-401.
72. Joos S, Otano-Joos Ml, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996;87:1571-8.
73. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392-9.
74. Savage KJ, Monti S, Kufok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-9.
75. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-62.
76. Gatter KC, Warnke RA. Intravascular large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:177-8.
77. Banks PM, Warnke RA. Primary effusion lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:179-80.
78. Jaffe ES, Wilson WH. Lymphomatoid granulomatosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours.Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:185-7.
79. Ganti AK, Weisenburger DD, Smith LM, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006;17:920-7.
80. Nathwani BN, Harris NL, Weisenburger D, et al. Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours.Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:162-7.
81. Bosga-Bouwer AG, van den Berg A, Haralambieva E, et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006;37:528-33.
82. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002;99:3806-12.
83. Diebold J, Jaffe ES, Raphael M, et al. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours.Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:181-4.
84. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-30.
85. Haralambieva E, Boerma E-J, van Imhoff GW, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005;29:1086-94.
86. Anon. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
87. Cogliatti SB, Novak U, Henz S, et al. Diagnosis of Burkitt lymphoma in due time: a practical approach. Br J Haematol 2006;134:294-301.
88. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354:2431-42.
89. Harris NL, Horning SJ. Burkitt's lymphoma - the message from microarrays. N Engl J Med 2006;354:2495-8.
90. Stein H, Hummel M. Histopathology in the light of molecular profiling. Ann Oncol 2006;17(Suppl 4):iv5-7.
91. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 2005;29:1652-60.
92. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-30.
93. Kanungo A, Medeiros U, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14,18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006;19:25-33.
94. Stamatoullas A, Buchonnet G, Lepretre S, et al. De novo acute B cell leukemia/lymphoma with t(14;18). Leukemia 2000;14:1960-6.
95. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt' s lymphoma. N Engl J Med 2006;354:2431-42.
96. Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 2001;97:3713-20.
97. Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003;27:1346-56.
98. Higgins JP, van de Rijn M, Jones CD, et al. Peripheral T-cell lymphoma complicated by a proliferation of large B cells. Am J Clin Pathol 2000;114:236-47.
99. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003;27:1513- 22.
100. Garcia JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005;47:101-10.
101. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005;29:1411-21.
102. Andriko JAW, Swerdlow SH, Aguilera NI, et al. Is lymphoplasmacytic lymphoma/immunocytoma a distinct entity? A clinicopathologic study of 20 cases. Am J Surg Pathol 2001;25:742-51.
103. de Jong D, Boot H, van Heerde P, et al. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology 1997;112:1466-74.
104. de Jong D, Vytb-Dreese F, Dellemijn T, et al. Histological and immunological parameters to predict treatment outcome of Helicobacter pylori eradication in low-grade gastric MALT lymphoma. J Pathol 2001;193:318-24.
105. Ferreri AJM, Freschi M, Dell'Oro S, et al. Prognostic significance of the histopathologic recognition of low- and high-grade components in stage I-II B-cell gastric lymphomas. Am J Surg Pathol 2001;25:95-102.
106. Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006;48:162-73.
107. Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003;27:762-71.
108. Lloret E, Mollejo M, Mateo MS, et al. Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant? Hum Pathol 1999;30:1153-60.